IP Library › Granted Patent US 12,187,769
Granted Patent B2
US 12,187,769 · App. 18/323,090 · Granted Jan 7, 2025

Cell

Inventors: Martin Pulé (London, GB); Shaun Cordoba (London, GB); Simon Thomas (London, GB); Shimobi Onuoha (London, GB); Matteo Righi (London, GB)
Assignee: AUTOLUS LIMITED
C07K14/4705A61K39/4611A61K39/4631A61K39/464404A61K39/464412C07K14/705C12N5/0637C12N15/62A61K2239/31A61K2239/47C07K2319/02C07K2319/20C07K2319/50C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,187,769
App. No.
18/323,090
Granted
Jan 7, 2025
Kind
B2
Abstract

The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.

Claims (8)

1. A cytolytic immune cell which comprises a CAR and an inducible Signal Transducer and Activator of Transcription (STAT) molecule,

wherein

(a) the STAT molecule comprises a first polypeptide comprising a first dimerizing domain (DD) and a second polypeptide comprising a second DD, which second DD specifically binds to the first DD; and wherein the presence of an agent causes dimerization of the first and second DD and induces activation of the STAT molecule, or

(b) the STAT molecule comprises a first polypeptide comprising a first dimerizing domain (DD) and a second polypeptide comprising a second DD, which second DD specifically binds to the first DD; and wherein the presence of an agent causes dissociation of the first and second DD and induces non-activation of the STAT molecule.

2. A cell according to claim 1 (a), wherein the first DD comprises FRB and the second DD comprises FKBP12 and the agent is rapamycin.

3. A cell according to claim 1 (b), wherein the first DD comprises Tet Repressor Protein (TetR) and the second DD comprises Transcription Inducing Peptide (TiP); and the agent is tetracycline, doxycycline or minocycline.

4. A pharmaceutical composition comprising a plurality of cells according to claim 1 .

5. A pharmaceutical composition according to claim 4 for use in treating and/or preventing a disease.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jul 30, 2026
From: AUTOLUS LIMITED
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 076084/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2024
From: PULÉ, MARTIN; CORDOBA, SHAUN; THOMAS, SIMON; ONUOHA, SHIMOBI; RIGHI, MATTEO
To: AUTOLUS LIMITED
Reel/Frame 066049/0444 →
Priority Claims (1)
GB 1714718 · Sep 13, 2017 · national
Continuity (2)
Division 16646906
Related Publication 20240075066A1 · Mar 7, 2024
References Cited (21)
US 20220025001A1 · Sentman et al. · 2022 [cited by applicant]
US 20220145325A1 · Puléet al. · 2022 [cited by applicant]
US 20220364116A1 · Puléet al. · 2022 [cited by applicant]
WO WO0109326A1 · 2001 [cited by applicant]
WO WO2015150771A1 · 2015 [cited by applicant]
WO WO2017029512A1 · 2017 [cited by applicant]
WO WO2017190100A1 · 2017 [cited by applicant]
WO WO2017218850A1 · 2017 [cited by applicant]
WO WO2020183131A1 · 2020 [cited by applicant]
Eyquem et al., Nature, 543, 113-117, Mar. 2017. [cited by examiner]
Baker et al., “Hematopoietic cytokine receptor signaling,” Oncogene 26:6724-6737 (2007). [cited by applicant]
Burchill et al., “Distinct Effects of STAT5 Activation on CD4+ and CD8+ T Cell Homeostasis: Development of CD4+ CD25+ Regulatory T Cells versus CD8+ Memory T Cells”, The Journal of Immunology, 171(11):5853-5864 (2003). [cited by applicant]
Ding et al., “IL-7 signaling imparts polyfunctionality and stemness potential to CD4+ T cells,” Oncoimmunology 5(6):e1171446, 13 pages (2016). [cited by applicant]
Hassuneh et al., “Evidence for the Participation of Interleukin-2 (IL-2) and IL-4 in the Regulation of Autonomous Growth and Tumorigenesis of Transformed Cells of Lymphoid Origin,” Blood 89:610-620 (1997). [cited by applicant]
Hurton et al., “Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells,” PNAS 113(48):E7788-E7797 (2016). [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/GB2018/052583 dated Nov. 23, 2018. [cited by applicant]
Kagoya et al., “A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects,” Nat Med 24(3):352-359 (2018). [cited by applicant]
Milner et al., “Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations,” Blood 125:591-599 (2015). [cited by applicant]
Nagarkatti et al., “Constitutive activation of the interleukin 2 gene in the induction of spontaneous in vitro transformation and tumorigenicity of T cells,” Proc. Natl. Acad. Sci. 91:7638-7642 (1994). [cited by applicant]
Onishi et al., “Identification and Characterization of a Constitutively Active STAT5 Mutant That Promotes Cell Proliferation,” Molecular and Cellular Biology 18(7):3871-3879 (1998). [cited by applicant]
Vogtenhuber et al., “Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses,” Blook 116(3):4… [cited by applicant]
Cited By (1)
US 12,492,410